# October 9, 2026 — scheduled focused research update

[Home](../README.md) · [Latest](../LATEST.md) · [Milestones](../MILESTONES.md)

Focused review of 32 active condition topics in six groups, with the retained Sleep hub read as inherited history rather than a duplicate monitoring assignment. Searches use the last full successful check plus a seven-day overlap, with preceding ninety-day context for unfinished baselines. New findings below are newly appraised, with their original source dates; older context is labeled baseline. Every incomplete review retains its full-topic successful-check date.

## Findings

- **2026-10-01 — Sponsor-reported randomized phase 2 results; conference presentation; publication described as in press:** [COURAGE reports one-year lean-tissue preservation with low-dose trevogrumab](../topics/04_muscle.md#note-2026-10-01-courage52).
- **2026-10-02 — Peer-reviewed randomized sham-controlled trial; accepted early article and abstract:** [Sham-controlled knee-radiotherapy trial finds a temporary responder benefit](../topics/11_joint_preservation.md#note-2026-10-02-lordknea).
- **2026-10-08 — Sponsor-only randomized phase 2 topline:** [FB102 meets a celiac gluten-challenge histology endpoint; clinical detail remains limited](../topics/15_autoimmune.md#note-2026-10-08-fb102).
- **2026-10-02 — Sponsor-reported phase 2 extension and conference data:** [Litifilimab adds one-year cutaneous-lupus follow-up after placebo crossover](../topics/15_autoimmune.md#note-2026-10-02-litifilimab).
- **2026-10-08 — Sponsor-reported phase 3 recruitment milestone:** [SL1002 completes pivotal knee-pain enrollment; readout forecast for Q2 2027](../topics/16_pain.md#note-2026-10-08-sl1002).
- **2026-10-09 — Trial-registry recruitment update:** [Suzetrigine’s long-term diabetic-neuropathy study closes recruitment](../topics/16_pain.md#note-2026-10-09-suzetriginedpn).
- **2026-10-08 — New human phase 3 trial registration:** [New randomized knee-replacement study tests suzetrigine’s opioid-sparing effect](../topics/16_pain.md#note-2026-10-08-suzetriginetka).
- **2026-10-09 — New human phase 3 trial registration:** [Tilrekimig registers a recruiting phase 3 severe-asthma trial](../topics/26_allergy_airway.md#note-2026-10-09-tilrekimig).
- **2026-10-07 — New randomized human phase 2 trial registration:** [RSV study compares vaccine strategies after lung or stem-cell transplantation](../topics/27_infectious_disease.md#note-2026-10-07-rsvtransplant).
- **2026-10-07 — Sponsor-only topline from randomized double-blind placebo-controlled human trial:** [Petrelintide reports phase 2b weight and HbA1c results in type 2 diabetes](../topics/03_glp1.md#note-2026-10-07-zupreme2).
- **2026-10-07 — Sponsor statement corroborated by recruiting registries; no efficacy results:** [Petrelintide phase 3 first treatment is confirmed](../topics/03_glp1.md#note-2026-10-07-petrelintide-phase3-start).
- **2026-10-09 — New formal randomized human-trial protocols; not yet recruiting:** [Oral VK2735 registers the SUNRISE phase 3 trials](../topics/03_glp1.md#note-2026-10-09-oral-vk2735-sunrise).
- **2026-10-09 — New phase 1 open-label human-trial registration:** [New trial studies tolerability when switching from tirzepatide to zenagamtide](../topics/03_glp1.md#note-2026-10-09-zenagamtide-switch).
- **2026-10-08 — Informal trial-participant report — unconfirmed:** [Anonymous SOLIS-1 participant describes vomiting, drowsiness and tremor after dose escalation](../topics/03_glp1.md#note-2026-10-08-solis1-informal).
- **2026-10-01 — Peer-reviewed single-centre phase 2 proof-of-principle randomized double-blind placebo-controlled trial:** [Small randomized senolytic MASH trial reports a biopsy signal and more adverse events](../topics/13_liver.md#note-2026-10-01-truth-senolytics).
- **2026-10-08 — Dated sponsor regulatory-filing announcement; review, not approval:** [FDA accepts finerenone application for chronic kidney disease without diabetes](../topics/17_kidney.md#note-2026-10-08-finerenone-nondiabetic-filing).
- **2026-10-07 — Sponsor-only small open-label single-dose human data plus scheduled primary conference abstract:** [PYC-003 reports exploratory target engagement in inherited polycystic kidney disease](../topics/17_kidney.md#note-2026-10-07-pyc003-target-engagement).
- **2026-10-09 — Historical baseline; Live investigator-site status; original launch date unverified:** [Farabursen phase 3 recruitment is listed at Tufts](../topics/17_kidney.md#note-2026-10-09-farabursen-tufts-baseline).
- **2026-09-16 — Historical baseline; Registered phase 4 randomized double-blind sequential trial; baseline recovery, no results:** [Large pragmatic trial compares commonly used insomnia medicines](../topics/29_sleep_insomnia.md#note-2026-09-16-smart-insomnia-baseline).
- **2026-09-29 — New investigator randomized open-label comparative-effectiveness protocol; no results:** [New trial will compare tirzepatide with PAP for apnea treatment effectiveness](../topics/30_sleep_apnea.md#note-2026-09-29-tirze-pap).
- **2026-09-17 — Historical baseline; Registered phase 3 randomized masked placebo-controlled trial; baseline expansion:** [Monthly berobenatide is being studied in OSA with PAP](../topics/30_sleep_apnea.md#note-2026-09-17-vesper-osa1-baseline).
- **2026-07-09 — Historical baseline; Registered phase 3 randomized-withdrawal trial; older baseline recovery:** [XYRISE studies expanded Xywav dosing in narcolepsy and idiopathic hypersomnia](../topics/31_sleep_hypersomnolence.md#note-2026-07-09-xyrise-baseline).
- **2026-05-26 — Historical baseline; Peer-reviewed expert consensus/practice algorithm; historical baseline, not new October trial data:** [Updated RLS treatment algorithm supplies a current clinical context](../topics/33_sleep_restless_legs.md#note-2026-05-26-rls-algorithm2026-baseline).
- **2026-10-08 — Historical baseline; Registered phase 2 randomized masked human study; baseline recovery, no results:** [A placebo-controlled CBD-extract trial is planned for idiopathic RLS](../topics/33_sleep_restless_legs.md#note-2026-10-08-brc002-baseline).
- **2026-08-21 — Historical baseline; Registered prospective single-arm first-in-indication feasibility study; baseline recovery:** [An implanted spinal-cord stimulation feasibility study is planned for refractory RLS](../topics/33_sleep_restless_legs.md#note-2026-08-21-norlsscs-baseline).
- **2026-10-07 — Sponsor-funded secondary analysis of randomized NHS-Galleri data; national impact is modeled:** [EDCC poster reports fewer emergency cancer diagnoses with Galleri](../topics/02_galleri.md#edcc-poster-reports-fewer-emergency-cancer-diagnoses-with-galleri).
- **2026-10-06 — Sponsor-funded post hoc statistical modeling of randomized screening data:** [NHS-Galleri model estimates a preclinical detection window](../topics/02_galleri.md#nhs-galleri-model-estimates-a-preclinical-detection-window).
- **2026-10-07 — Sponsor-funded descriptive conference subgroup analysis:** [PATHFINDER 2 subgroup analysis leaves uncertainty about equal performance](../topics/02_galleri.md#pathfinder-2-subgroup-analysis-leaves-uncertainty-about-equal-performance).
- **2026-10-07 — Sponsor-funded uncontrolled retrospective insurance-claims analysis:** [Claims analysis finds no mammography decline after a negative Galleri result](../topics/02_galleri.md#claims-analysis-finds-no-mammography-decline-after-a-negative-galleri-result).
- **2026-10-07 — Sponsor-funded descriptive categorization of cancers detected in two existing trials:** [Galleri poster catalogs histologic cancer types rather than 204 independent screening targets](../topics/02_galleri.md#galleri-poster-catalogs-histologic-cancer-types-rather-than-204-independent-screening-targets).
- **2026-09-22 — Historical baseline; Verified phase 2 human trial registry; historical baseline gap repair:** [Baseline recovered: TREMHANCE is recruiting for oral SAR448851](../topics/08_alzheimers.md#baseline-recovered-tremhance-is-recruiting-for-oral-sar448851).
- **2026-09-18 — Recovered recent randomized phase 2 human trial registration:** [SAGITTARIUS registers an amyloid vaccine trial before cognitive impairment](../topics/08_alzheimers.md#sagittarius-registers-an-amyloid-vaccine-trial-before-cognitive-impairment).
- **2026-09-14 — Recovered recent randomized phase 1 human trial registration:** [MLS101 registers a low-dose psilocybin trial for PMDD](../topics/09_psychedelics.md#mls101-registers-a-low-dose-psilocybin-trial-for-pmdd).
- **2026-10-09 — Sponsor-reported FDA approval corroborated by approved U.S. prescribing information; FDA letter not independently retrieved:** [Teva announces U.S. approval of monthly subcutaneous olanzapine](../topics/10_ssri_antidepressants.md#teva-announces-u-s-approval-of-monthly-subcutaneous-olanzapine).
- **2026-10-05 — New formal randomized human neuromodulation trial registration:** [FEAST-AFT registers a focused-seizure-therapy comparison in depression](../topics/10_ssri_antidepressants.md#feast-aft-registers-a-focused-seizure-therapy-comparison-in-depression).
- **2026-10-07 — Randomized phase 2/3 trial publication; primary investigator release appraised, full paper inaccessible:** [NRG-BR002 publication finds no added survival benefit from ablating breast-cancer metastases](../topics/14_cancer_vaccines.md#nrg-br002-publication-finds-no-added-survival-benefit-from-ablating-breast-cancer-metastases).
- **2026-10-06 — New formal randomized phase 2 human trial registration:** [ImmProCure registers a vaccine and bispecific trial for prostate-cancer recurrence](../topics/14_cancer_vaccines.md#immprocure-registers-a-vaccine-and-bispecific-trial-for-prostate-cancer-recurrence).
- **2026-10-06 — New formal phase 2 human trial registration:** [VA registers a LabVax combination study in advanced lung adenocarcinoma](../topics/14_cancer_vaccines.md#va-registers-a-labvax-combination-study-in-advanced-lung-adenocarcinoma).
- **2026-10-07 — Two new early-phase human trial registrations; no patient results:** [New GPC3 and MET antibody-drug conjugates enter the human-trial registry](../topics/14_cancer_vaccines.md#new-gpc3-and-met-antibody-drug-conjugates-enter-the-human-trial-registry).
- **2026-09-28 — Sponsor-reported human phase 2 follow-up and phase 3 enrollment, with October9 registry corroboration:** [4D-150 expands into phase 3 for diabetic macular edema](../topics/18_hearing_vision.md#4d-150-expands-into-phase-3-for-diabetic-macular-edema).
- **2026-10-08 — Peer-reviewed observational germline sequencing cohort; official journal and investigator reporting appraised:** [Large cancer cohort finds inherited variants beyond early-onset cases](../topics/28_genetic_screening.md#large-cancer-cohort-finds-inherited-variants-beyond-early-onset-cases).
- **2026-10-06 — Official investigator announcement of planned prospective human implementation research:** [Yale plans a 5,000-person primary-care genomic-screening pilot](../topics/28_genetic_screening.md#yale-plans-a-5-000-person-primary-care-genomic-screening-pilot).
- **2026-10-07 — New human pilot registration; no results:** [SCULPT registers a small placebo-controlled topical fat and cellulite study](../topics/06_localized_fat.md#note-2026-10-07-sculpt).
- **2026-10-09 — Sponsor conference poster and supplemental slides; selected Phase 3 extension analysis:** [Actual BRAVE-AA-PEDS poster shows maintenance among selected adolescent responders](../topics/19_hair_loss.md#note-2026-10-09-baricitinib).
- **2026-09-22 — Sponsor-submitted registry results; newly appraised older source:** [PP405 posted Phase 2a results add arm-level safety, without regrowth estimates](../topics/19_hair_loss.md#note-2026-09-22-pp405).
- **2026-10-07 — New human trial registration; no outcomes:** [Botulinum toxin versus nanofat pattern-hair-loss study enters the registry](../topics/19_hair_loss.md#note-2026-10-07-botoxnanofat).
- **2026-06-01 — Historical baseline; Peer-reviewed uncontrolled human series; historical baseline:** [Recovered baseline: ultrasound laxity series has mixed objective and subjective outcomes](../topics/20_skin_aging.md#note-2026-06-01-sofwave).
- **2026-09-27 — Peer-reviewed accepted randomized split-scar trial; abstract-level appraisal:** [Silicone-tape scar trial reports appearance benefit, with substantial attrition](../topics/21_scars.md#note-2026-09-27-siliconetape).
- **2026-10-02 — Peer-reviewed within-scar comparative trial; full HTML appraised:** [Small burn-scar comparison does not establish a clear total-score advantage for botulinum add-on](../topics/21_scars.md#note-2026-10-02-botoxlaser).
- **2026-09-14 — Sponsor commercial forecast with FDA approval cross-check; older source newly recovered:** [Recovered U.S. filler launch forecasts separate availability from earlier approval](../topics/22_facial_volume.md#note-2026-09-14-belotero).
- **2026-10-08 — New Phase 3 trial registration; no results:** [Povorcitinib adds a separate registered Chinese Phase 3 vitiligo trial](../topics/23_pigmentation.md#note-2026-10-08-povorcn).
- **2026-10-09 — Primary Phase 3 registration plus dated sponsor development statement; no U.S. results:** [AURORA registry now lists recruitment; sponsor reports sites activated](../topics/24_acne_rosacea.md#note-2026-10-09-aurora).
- **2026-10-08 — New trial registration; no results:** [B244 microbiome spray adds a registered Phase 2b acne study](../topics/24_acne_rosacea.md#note-2026-10-08-b244).
- **2026-10-09 — New Phase 2 human registration; no results:** [Small periodontal extracellular-vesicle trial enters the human registry](../topics/25_dental.md#note-2026-10-09-gmscev).

## Coverage by topic

### Whole-body MRI

**Coverage: focused_incomplete.** 0 newly recorded entries.

**Searches:** whole body MRI screening HERCULES results October2026 September2026; whole-body MRI October2026 results screening study; Levels whole body MRI healthy people Durand October1 2026

**Remaining gaps:** Read current topic/state and September5 overlap; all named registry records retrieved using live CT.gov API. HERCULES remains recruiting in an April2025 record; no result posted and its future completion dates remain estimates.; Opened October1 Levels original episode313 full transcript; reappraised October1 JGIM review already saved October6, therefore no duplicate event. New discovery matches were diagnostic/prostate-treatment imaging or unrelated studies, not a qualifying repeated-screening outcome trial.; International registries, long-term outcomes and all imaging-policy changes remain incompletely searched. Prenuvo research-network enrollment statements are undated and were not treated as a dated new milestone.

**Informal sources and unresolved claims:** Original Levels episode313, October1, DrDanielDurand/Prenuvo CMO with MikeHaney, full transcript now accessible. At52:35 and the corresponding transcript he predicts routine scans becoming commonplace; longitudinal-baseline benefits remain opinion/hypothesis, not new controlled outcomes. No distinct development rumor selected. Podcast census remains incomplete.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT06212479)
- [Source 2](https://clinicaltrials.gov/api/v2/studies?query.term=%28whole+body+MRI%29+AND+AREA%5BStudyFirstPostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json)
- [Source 3](https://www.levels.com/podcasts/whole-body-mri-healthy-people-durand)
- [Source 4](https://link.springer.com/article/10.1007/s11606-026-10802-y)
- [Source 5](https://www.prenuvoresearchnetwork.org/)

### Galleri and organ-specific cancer screening

**Coverage: focused_incomplete.** 5 newly recorded entries.

**Searches:** Galleri EDCC October6 7 8 2026 poster results; cancer screening colorectal screening mammography trial first posted October2–9 2026; site:reddit.com Galleri October2026 after:2026-10-05 before:2026-10-10

**Remaining gaps:** Read current topic/state and September5 overlap; live API retrieved all six saved registries, including October6 Vanguard update. Registry administrative refresh is not a new results announcement.; Closed prior EDCC gap: appraised actual October6–7 sponsor PDFs for emergency routes, detection-window modeling, health equity, mammography adherence, cancer spectrum and stage-associated life-expectancy modeling. Exact hub posting dates retained separately from conference6–8 window.; Organ-specific breast/colorectal/lung/precancer programs received targeted discovery searches; not an exhaustive registry/publication census. FDA September23 panel follow-through and labels were not independently reappraised in full. Life-expectancy-by-stage modeling not promoted as observed screening survival benefit.

**Informal sources and unresolved claims:** Targeted original Reddit/Galleri and informal meeting searches did not yield a distinct attributable fresh rumor. This is a limited search, not proof there are no rumors; no inference of FDA approval from an advisory vote or poster.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT04136002)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT04144738)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT05155605)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT05611632)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT05673018)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT06995898)
- [Source 7](https://clinicaltrials.gov/api/v2/studies?query.term=%28cancer+screening%29+AND+AREA%5BStudyFirstPostDate%5DRANGE%5B2026-10-02%2C2026-10-09%5D&pageSize=100&format=json)
- [Source 8](https://grail.com/wp-content/uploads/2026/10/EDCC-2026_Ellis_Routes-to-Dx_Poster_FINAL.pdf)
- [Source 9](https://grail.com/wp-content/uploads/2026/10/EDCC-2026_Hubbell_PS-Screening-Interval_FINAL.pdf)
- [Source 10](https://grail.com/wp-content/uploads/2026/10/EDCC-2026_Demeure_Health-Equity-Poster_FINAL-1.pdf)
- [Source 11](https://grail.com/wp-content/uploads/2026/10/EDCC-2026_McDonnell_MammographyAdherenceMCED_Poster_FINAL.pdf)
- [Source 12](https://grail.com/wp-content/uploads/2026/10/EDCC-2026_Clarke_PS-MCED-Detectable-Cancer-Types_Poster_FINAL-1.pdf)
- [Source 13](https://grail.com/clinical-evidence/)
- [Source 14](https://grail.com/wp-content/uploads/2026/10/EDCC-2026_Gray_Years-of-Life-Lost_Poster_FINAL.pdf)

### GLP-1 and related metabolic therapies

**Coverage: focused_incomplete.** 5 newly recorded entries.

**Searches:** ClinicalTrials.gov interventional discovery, LastUpdatePostDate September 5–October 9; updated named records from current topic pages.; Dated official sponsor, regulator, trial/publication, conference and original informal-source searches, with October 7–9 prioritized after the October 6 review.

**Remaining gaps:** Window: September 5–October 9, 2026, retaining the seven-day overlap from the last full successful check on September 12. October 6 findings were deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; GLP1 broad discovery returned 767 records; first 100 downloaded; selected relevant records screened; pagination and a worldwide entrant, safety/hold, formulation/approval census remain incomplete. Raw named records refreshed without treating routine edits as news. Root owns October 1 COURAGE; cross-link rather than duplicate. ZUPREME-2 exact dose mapping and complete harms/estimand tables unreleased.

**Informal sources and unresolved claims:** Oct8 original SOLIS-1 self-report and Oct9 comments retrieved through indexed original thread after direct fetch failure. Pfizer official study page independently matches GLP-1+dual amylin/calcitonin mechanism, but patient identity, allocation and causal attribution cannot be verified. Prior EloraTZP near-30% rumor remains unconfirmed; no new formal matching readout recovered. Full EASD/podcast audio and source-chain census remain incomplete.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT05567796)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT05726227)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT05882045)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT05929066)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT05929079)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT06388187)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT06534411)
- [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT06603571)
- [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT06628362)
- [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT06973681)
- [Source 11](https://clinicaltrials.gov/api/v2/studies/NCT07310901)
- [Source 12](https://clinicaltrials.gov/api/v2/studies/NCT07841860)
- [Source 13](https://clinicaltrials.gov/api/v2/studies?query.term=%28obesity+OR+overweight+OR+GLP-1%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true)
- [Source 14](https://www.globenewswire.com/de/news-release/2026/10/07/3376750/0/en/zealand-pharma-announces-positive-phase-2-zupreme-2-topline-results-for-amylin-analog-petrelintide-in-people-with-overweight-or-obesity-and-type-2-diabetes.html)
- [Source 15](https://clinicaltrials.gov/study/NCT06926842)
- [Source 16](https://clinicaltrials.gov/study/NCT07843498)
- [Source 17](https://clinicaltrials.gov/study/NCT07843485)
- [Source 18](https://clinicaltrials.gov/study/NCT07843472)
- [Source 19](https://clinicaltrials.gov/study/NCT07868835)
- [Source 20](https://clinicaltrials.gov/study/NCT07868939)
- [Source 21](https://clinicaltrials.gov/study/NCT07868354)
- [Source 22](https://www.reddit.com/r/GLP1ResearchTalk/comments/1x0wctl/glp1dacra_combo_trial/)
- [Source 23](https://www.pfizerclinicaltrials.com/nct07575932-overweight-or-obesity-trial)

### Muscle building and preservation

**Coverage: focused_incomplete.** 1 newly recorded entries.

**Searches:** Official named-program registry refresh; paginated discovery September 5–October 9, 2026; Dated sponsor, regulator, paper and conference searches; original Reddit and selected podcast/interview leads

**Remaining gaps:** All saved named NCT records refreshed and all pages of official overlap discovery screened (23 returned records). Search starts September 5/6 from the last full successful check, not October 6 alone. Incidental matches excluded; literature, international registries, all regulatory files and complete podcast/audio appraisal remain incomplete.; BELIEVE full withdrawal tables and HOPE-3 extension adverse-event tables remain missing. The October 7 PPMD webpage is still an invitation; a third-party transcript indicates a discussion but no original replay was appraised, so its elapsed date is not a new numerical result.

**Informal sources and unresolved claims:** Read October 1 original NTNPerformance repost of the COURAGE release; it supplies no independent corroboration. A BiohackingU October 7 comment calls trevogrumab phase 3, but the original sponsor/registry specify phase 2; gray-market sourcing context excluded. Revisited the September 9 Cantor enobosarm direction via third-party transcript; no actual phase 3 initiation confirmed, original audio unreviewed, stable claim remains unconfirmed without repeat alert.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT05156320)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT05616013)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT06299098)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT06411288)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT06445075)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT06643728)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT06901349)
- [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT07777575)
- [Source 9](https://clinicaltrials.gov/api/v2/studies?query.term=%28myostatin+OR+bimagrumab+OR+enobosarm+OR+%22muscle+preservation%22+OR+deramiocel%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json)
- [Source 10](https://investor.regeneron.com/news-releases/news-release-details/phase-2-courage-trial-confirms-trevogrumab-prevents-lean-mass)
- [Source 11](https://clinicaltrials.gov/study/NCT06299098)
- [Source 12](https://www.reddit.com/r/NTNPerformance/comments/1wv420d/phase_2_courage_trial_confirms_trevogrumab/)
- [Source 13](https://www.investing.com/news/transcripts/veru-at-12th-annual-cantor-fitzgerald-global-healthcare-conference-muscle-focus-93CH-4894905)
- [Source 14](https://www.parentprojectmd.org/events/community-webinar-capricor-therapeutics-overview-of-new-hope-3-2-year-ole-data/)

### Longevity and healthspan trials

**Coverage: focused_incomplete.** 0 newly recorded entries.

**Searches:** ClinicalTrials.gov interventional discovery, LastUpdatePostDate September 5–October 9; updated named records from current topic pages.; Dated official sponsor, regulator, trial/publication, conference and original informal-source searches, with October 7–9 prioritized after the October 6 review.

**Remaining gaps:** Window: September 5–October 9, 2026, retaining the seven-day overlap from the last full successful check on September 12. October 6 findings were deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; All 47 matches in the bounded longevity registry discovery were downloaded; broad terms still include disease-specific programs and not a comprehensive global geroscience census. Named RESTOR, MAVRIC, metformin/everolimus and IPACE-HIV records refreshed.; AFAR TAME official page retrieval failed again. Funded launch cannot be refreshed. Full original audio and complete mTOR/senolytic safety/publication census remain gaps.; Newly recovered TRUTH MASH trial belongs to liver; disease-specific biopsy response does not complete the longevity baseline or establish healthier/longer life.

**Informal sources and unresolved claims:** Revisited PEARL24month claim: newly located USA Longevity Today page asserts September 17 Nature Aging primary publication; direct page fetch failed, matching Nature Aging paper not located in exact search. This is another unconfirmed assertion, not independent corroboration of prior Vitaei claim; no repeat efficacy alert. Oct9 Futurology framing of MASH cure reviewed against original paper. Audio not fully reviewed.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT02570672)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT04221750)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT04313634)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT04488601)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT04742777)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT05835999)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT05938920)
- [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT06658093)
- [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT07144293)
- [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT07302932)
- [Source 11](https://clinicaltrials.gov/api/v2/studies/NCT07475546)
- [Source 12](https://clinicaltrials.gov/api/v2/studies/NCT07520110)
- [Source 13](https://clinicaltrials.gov/api/v2/studies?query.term=%28senolytic+OR+rapamycin+OR+metformin+aging+OR+healthspan%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true)
- [Source 14](https://www.nature.com/articles/s42255-026-01643-4)
- [Source 15](https://www.afar.org/tame-trial)
- [Source 16](https://usalongevitytoday.com/rapamycins-first-randomized-human-aging-trial-posts-its-data/)

### Localized fat removal and cellulite

**Coverage: focused_incomplete.** 1 newly recorded entries.

**Searches:** localized_fat: named programs and broader human-study discovery, September 5–October 9, with priority to October 6–9.; localized_fat: original Reddit posts, podcast/talk descriptions and unresolved saved informal claims.; Europe PMC FIRST_PDATE September 5–October 9 failed HTTP503; targeted web primary literature used as partial fallback.

**Remaining gaps:** Read the current assigned topic and canonical scope/state. Named original registry records refreshed; all pages of broad ClinicalTrials.gov discovery for September 5–October 9 were retrieved (205 records, with incidental matches excluded). This honors the seven-day overlap from the saved September 12 full successful check.; Europe PMC original-literature discovery again returned HTTP 503. Targeted primary publisher, sponsor and conference searches were performed, but the worldwide paper/regulator/procedure and original-audio census remains incomplete. Preserve last_successful_check_utc.; SUPREME-01 remains recruiting 320, last posted September 22; CBL-0206 records, AYP-101 completed/no results, tesamorelin and RZL-012 records retain saved status. Caliway index still ends with October 2 EASD report. No new SUPREME-02, China NDA filing or broader tesamorelin indication verified.; A newly posted Assiut 40-person double-chin cohort NCT07864246 is not yet recruiting and has only one broadly described group; no randomized modality comparison or result. Not promoted as efficacy. Full original CBL-514 EASD tables, cellulite comparative census and regulator/rare-harm review remain gaps.

**Informal sources and unresolved claims:** October 7 BodyHackGuide thread https://www.reddit.com/r/BodyHackGuide/comments/1wzmfif/down_30_on_rt_what_else_to_add/ and October 9 tesamorelin/blend discussion are self-experimentation, not formal-program outcomes or attributable development forecasts. Existing CBL-514 sourcing threads were deduplicated. No new rumor selected; full investor/podcast recordings incomplete.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT00675506)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT02196831)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT03375788)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT04867434)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT05445557)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT05736107)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT06256445)
- [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT06303570)
- [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT07140939)
- [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT07481734)
- [Source 11](https://clinicaltrials.gov/api/v2/studies/NCT07608757)
- [Source 12](https://clinicaltrials.gov/api/v2/studies/NCT07608770)
- [Source 13](https://clinicaltrials.gov/api/v2/studies/NCT07802431)
- [Source 14](https://clinicaltrials.gov/api/v2/studies?query.term=%28CBL-514+OR+RZL-012+OR+tesamorelin+OR+cellulite+OR+%28regional+AND+fat%29%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json)
- [Source 15](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%28CBL-514+OR+RZL-012+OR+tesamorelin+OR+cellulite+OR+lipedema%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-09%5D&format=json&pageSize=100&resultType=core&sort=FIRST_PDATE_D)
- [Source 16](https://clinicaltrials.gov/study/NCT07862920)
- [Source 17](https://www.caliwaybiopharma.com/en/news/)
- [Source 18](https://clinicaltrials.gov/study/NCT07864246)

### Broad cardiovascular prevention, lipids and screening

**Coverage: focused_incomplete.** 0 newly recorded entries.

**Searches:** ClinicalTrials.gov interventional discovery, LastUpdatePostDate September 5–October 9; updated named records from current topic pages.; Dated official sponsor, regulator, trial/publication, conference and original informal-source searches, with October 7–9 prioritized after the October 6 review.

**Remaining gaps:** Window: September 5–October 9, 2026, retaining the seven-day overlap from the last full successful check on September 12. October 6 findings were deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; Broad discovery returned 494 records; first 100 downloaded; selected relevant records screened. Remaining pages and a worldwide lipid/gene-editing/safety census not completed. Saved AMBIENCE, REFINE-CAC and DR10624 October 6 entries retained rather than repeated.; Curbsiders October 5 original show page recovered after the prior fetch gap. It discusses established 2026 lipid guidance and awaiting inclisiran outcomes, not a new trial readout. Full YouTube transcript/audio not appraised.

**Informal sources and unresolved claims:** Original Curbsiders episode #541, October 5, Daniel Edmundowicz: show notes reviewed; LDL-target jokes and vaccine analogy not converted into medical recommendations. No full transcript/timestamp appraisal; no new attributable development rumor from this page.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT04023552)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT05079919)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT05202509)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT05552326)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT05581303)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT05636176)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT06008756)
- [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT06112418)
- [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT06164730)
- [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT06200207)
- [Source 11](https://clinicaltrials.gov/api/v2/studies/NCT06292013)
- [Source 12](https://clinicaltrials.gov/api/v2/studies/NCT07223658)
- [Source 13](https://clinicaltrials.gov/api/v2/studies/NCT07428473)
- [Source 14](https://clinicaltrials.gov/api/v2/studies/NCT07803679)
- [Source 15](https://clinicaltrials.gov/api/v2/studies/NCT07839936)
- [Source 16](https://clinicaltrials.gov/api/v2/studies/NCT07848880)
- [Source 17](https://clinicaltrials.gov/api/v2/studies/NCT07853716)
- [Source 18](https://clinicaltrials.gov/api/v2/studies/NCT07858019)
- [Source 19](https://clinicaltrials.gov/api/v2/studies/NCT07861100)
- [Source 20](https://clinicaltrials.gov/api/v2/studies?query.term=%28PCSK9+OR+lipoprotein+OR+coronary+plaque+OR+cholesterol%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true)
- [Source 21](https://thecurbsiders.com/curbsiders-podcast/541-a-walk-through-the-2026-lipid-management-guidelines)
- [Source 22](https://clinicaltrials.gov/study/NCT07861100)

### Alzheimer's screening and therapies

**Coverage: focused_incomplete.** 2 newly recorded entries.

**Searches:** Alzheimer therapy biomarker bloodtest clinical trial October2026 after:2026-10-05 before:2026-10-10; SAR448851 NCT07688213 TREMHANCE phase2; site:reddit.com/r/Alzheimers October2026 trialtreatment; ALN-5288 October2026

**Remaining gaps:** Read current topic/state and September5 overlap; all12 saved registry records,32 new-study search matches and recovered SAR448851 live record appraised for scope.; SAR448851 registry access gap closed, historical start July28 retained as baseline. Selected new prevention vaccine registration. No new efficacy inferred from registry refreshes for ClarityAD/PDE4PET/ALN-5288.; All antibody labels/ARIA changes, assay recalls, worldwide prevention cohorts and full blood-test outcomes inventory remain incomplete. Several new biomarker/device records require full appraisal before promotion.

**Informal sources and unresolved claims:** Opened original Oct7–8 r/Alzheimers treatment-or-not thread. It mixes anonymous personal experiences, unsupported universal-treatment claims, and long-delay figures apparently derived from modeling; none establishes new randomized efficacy/safety or individual benefit. Existing Attia/Davidson obicetrapib prevention hypothesis remains unconfirmed. No distinct new development rumor selected.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT03887455)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT04437511)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT04468659)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT04639050)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT05026866)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT05399888)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT06957418)
- [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT07169578)
- [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT07169630)
- [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT07170150)
- [Source 11](https://clinicaltrials.gov/api/v2/studies/NCT07214727)
- [Source 12](https://clinicaltrials.gov/api/v2/studies/NCT07794670)
- [Source 13](https://clinicaltrials.gov/api/v2/studies?query.term=%28Alzheimer%29+AND+AREA%5BStudyFirstPostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json)
- [Source 14](https://clinicaltrials.gov/study/NCT07688213)
- [Source 15](https://clinicaltrials.gov/study/NCT07827768)
- [Source 16](https://clinicaltrials.gov/api/v2/studies/NCT07688213)
- [Source 17](https://www.reddit.com/r/Alzheimers/comments/1x0192m/treatment_or_not/)

### Psilocybin and related therapies

**Coverage: focused_incomplete.** 1 newly recorded entries.

**Searches:** psychedelic COMP360 HLP003 GH001 trial results October2026; site:reddit.com/r/shroomstocks October2026 APPROACH; APPROACH psilocybin NCT September28 2026 completion; psilocybin lysergide mebufotenin MDMA newly registered September5 October9 2026

**Remaining gaps:** Read current topic/state, September5 overlap and all six saved trial records;13 newly registered search matches screened for psychedelic rather than incidental DMT abbreviation.; Selected formal PMDD study, with phase1 safety endpoints and supervised exposure explicit. Nicotine NCT07852832 is a three-person basic-science pilot, not cessation efficacy; ADEPT NCT07833761 and PEARL NCT07820033 were discovery leads not fully appraised.; APPROACH NCT06564818 surfaced via original Reddit and registry mirror; its live primary record still needs refresh, so Sept4 actual-completion claim not promoted. FDA hearing full transcript/outcome, all COMP/GH/Helus/Definium safety and complete international registry sweep remain gaps.

**Informal sources and unresolved claims:** Original Oct5 shroomstocks weekly thread contains speculation based on APPROACH registry dates; actual completion is not a topline announcement and no efficacy inference is justified. Oct8 investing post repeats COMP360 approval timing hopes without inside source. No material confirmation of saved MDMA resubmission rumor. Broader full podcast/talk review incomplete.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT05029466)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT05065294)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT05800860)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT06308653)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT06524830)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT06809595)
- [Source 7](https://clinicaltrials.gov/api/v2/studies?query.term=%28psilocybin+OR+lysergide+OR+mebufotenin+OR+DMT+OR+MDMA%29+AND+AREA%5BStudyFirstPostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json)
- [Source 8](https://clinicaltrials.gov/study/NCT07818720)
- [Source 9](https://www.reddit.com/r/shroomstocks/comments/1wy7z0a/rshroomstocks_weekly_discussion_thread_october_05/)
- [Source 10](https://www.reddit.com/r/investing_discussion/comments/1x0wsau/compass_pathways_cmps_first_fda_approved/)

### Mental-health treatments, SSRIs and newer antidepressants

**Coverage: focused_incomplete.** 2 newly recorded entries.

**Searches:** antidepressant anxiety OCD PTSD bipolar addiction clinical trial October2026 after:2026-10-05 before:2026-10-10; WELTRUZA October9 2026 FDA; site:reddit.com SSRI October2026 new trial

**Remaining gaps:** Read expanded diagnosis topic/state and saved19 registries. Appraised Oct9 Teva release plus actual45-page approved label for new olanzapine formulation, not an antidepressant claim.; New-study search returned100 with another page not retrieved; broad query contains many incidental depression/trauma terms. FEAST-AFT selected with active-comparator and primary quality-of-life endpoint preserved.; OCD/PTSD/anxiety/addiction/bipolar full pipeline, all SSRI long-term harms and formal label/guideline changes remain incompletely reviewed. WELTRUZA is included explicitly as schizophrenia/formulation-specific within broad mental-health treatment, without antidepressant/bipolar extrapolation.

**Informal sources and unresolved claims:** Targeted original Reddit and new-program informal searches performed. Oct9 WELTRUZA Reddit post traces to public approval release rather than a separate rumor. Older emotional-blunting anecdotes and fluoxetine-reanalysis commentary do not constitute new development signals. Full podcasts/Q&A census incomplete.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT02978326)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT04019704)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT04138680)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT04442503)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT04599855)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT05113771)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT05147142)
- [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT05895643)
- [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT05966155)
- [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT06462586)
- [Source 11](https://clinicaltrials.gov/api/v2/studies/NCT06785012)
- [Source 12](https://clinicaltrials.gov/api/v2/studies/NCT07218354)
- [Source 13](https://clinicaltrials.gov/api/v2/studies/NCT07393919)
- [Source 14](https://clinicaltrials.gov/api/v2/studies/NCT07810738)
- [Source 15](https://clinicaltrials.gov/api/v2/studies/NCT07824206)
- [Source 16](https://clinicaltrials.gov/api/v2/studies/NCT07824973)
- [Source 17](https://clinicaltrials.gov/api/v2/studies/NCT07839338)
- [Source 18](https://clinicaltrials.gov/api/v2/studies/NCT07857629)
- [Source 19](https://clinicaltrials.gov/api/v2/studies?query.term=%28depression+OR+obsessive+compulsive+OR+PTSD+OR+addiction+OR+bipolar%29+AND+AREA%5BStudyFirstPostDate%5DRANGE%5B2026-10-02%2C2026-10-09%5D&pageSize=100&format=json)
- [Source 20](https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Announces-U-S--Food-and-Drug-Administration-FDA-Approval-of-WELTRUZA-Olanzapine-For-Extended-Release-Injectable-Suspension-as-the-First-and-Only-Once-Monthly-Subcutaneous-Injectable-Olanzapine-for-Adults-with-Schizophrenia/default.aspx)
- [Source 21](https://www.weltruza.com/globalassets/weltruza/prescribing-information.pdf)
- [Source 22](https://clinicaltrials.gov/study/NCT07857122)
- [Source 23](https://www.weltruza.com/)
- [Source 24](https://www.reddit.com/r/MarketFluxHub/comments/1x1mnqz/fda_approves_tevas_weltruza_as_first_oncemonthly/)

### Bone health, joint preservation and cartilage repair

**Coverage: focused_incomplete.** 1 newly recorded entries.

**Searches:** Official named-program registry refresh; paginated discovery September 5–October 9, 2026; Dated sponsor, regulator, paper and conference searches; original Reddit and selected podcast/interview leads

**Remaining gaps:** All saved named NCT records refreshed and all pages of official overlap discovery screened (96 returned records). Search starts September 5/6 from the last full successful check, not October 6 alone. Incidental matches excluded; literature, international registries, all regulatory files and complete podcast/audio appraisal remain incomplete.; No new ACTiVION-I October topline or lorecivivint regulatory decision verified. Cartilage-cell and osteoporosis programs refreshed in registries; complete fracture/sequencing literature remains incomplete. EB613 October 9/11 ASBMR slots were recovered from an August announcement; no new efficacy inferred before presentation.

**Informal sources and unresolved claims:** Original Osteoarthritis Reddit discovery returned recycled lorecivivint/sprifermin forecasts and injection anecdotes rather than a dated new formal-development claim. Broad original podcast review remains a gap.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT01463813)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT01919164)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT02566655)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT03203330)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT03291470)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT03868033)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT04385303)
- [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT04520607)
- [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT05391776)
- [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT06400862)
- [Source 11](https://clinicaltrials.gov/api/v2/studies/NCT07112443)
- [Source 12](https://clinicaltrials.gov/api/v2/studies/NCT07339111)
- [Source 13](https://clinicaltrials.gov/api/v2/studies/NCT07806331)
- [Source 14](https://clinicaltrials.gov/api/v2/studies?query.term=%28osteoporosis+OR+%22cartilage+repair%22+OR+lorecivivint+OR+%22TG-C%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json)
- [Source 15](https://link.springer.com/article/10.1186/s12916-026-05287-9)
- [Source 16](https://clinicaltrials.gov/study/NCT05562271)
- [Source 17](https://www.tissuegene.com/en_US/investors/pr)
- [Source 18](https://www.globenewswire.com/news-release/2026/08/04/3338306/0/en/entera-bio-phase-2-data-supporting-eb613-s-oral-pth-1-34-anabolic-effect-on-postmenopausal-women-with-osteoporosis-at-high-risk-for-fracture-selected-for-plenary-poster-session-pre.html)
- [Source 19](https://www.reddit.com/r/Osteoarthritis/comments/1uk0kl0/one_injection_reversed_osteoarthritis_in_weeks/)

### Liver health and noninvasive assessment

**Coverage: focused_incomplete.** 1 newly recorded entries.

**Searches:** ClinicalTrials.gov interventional discovery, LastUpdatePostDate September 5–October 9; updated named records from current topic pages.; Dated official sponsor, regulator, trial/publication, conference and original informal-source searches, with October 7–9 prioritized after the October 6 review.

**Remaining gaps:** Window: September 5–October 9, 2026, retaining the seven-day overlap from the last full successful check on September 12. October 6 findings were deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; Liver discovery returned 171 records; first 100 downloaded; selected relevant records screened, remaining page not reviewed. Updated saved RNA-interference protocols rechecked. September 29 TRIUMPH-1 full methods/CI access gap and worldwide noninvasive-screening/approval coverage remain.

**Informal sources and unresolved claims:** October 9 original r/Futurology post located: https://www.reddit.com/r/Futurology/comments/1x1lwvz/in_a_world_first_in_a_phase_2_trial_with_31/ . It frames histologic MASH resolution as a 50+% cure rate; original trial supports a short-term biopsy outcome, not proven durable cure. This is interpretation of a published paper, not a new clinical leak. Wider podcast audio and existing European Wegovy-MASH rumor not comprehensively refreshed.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT03900429)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT04822181)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT04849728)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT05039450)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT05500222)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT06161571)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT06215716)
- [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT06528314)
- [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT07427680)
- [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT07854782)
- [Source 11](https://clinicaltrials.gov/api/v2/studies/NCT07859813)
- [Source 12](https://clinicaltrials.gov/api/v2/studies?query.term=%28MASH+OR+NASH+OR+liver+fibrosis%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true)
- [Source 13](https://www.nature.com/articles/s42255-026-01643-4)
- [Source 14](https://clinicaltrials.gov/study/NCT05506488)
- [Source 15](https://www.reddit.com/r/Futurology/comments/1x1lwvz/in_a_world_first_in_a_phase_2_trial_with_31/)

### Cancer treatment, vaccines and recurrence prevention

**Coverage: focused_incomplete.** 4 newly recorded entries.

**Searches:** cancer vaccine ADC radiopharmaceutical newly registered October2–9 2026; NRG-BR002 October7 2026 metastasis directed trial; site:ir.sellaslifesciences.com REGAL October2026 80 events; site:reddit.com cancer vaccine October2026 REGAL

**Remaining gaps:** Read broad oncology topic/state, September5 overlap, registry collection and Oct2–9 new-study discovery. No duplicate evERA, IMpassion050, daraxonrasib, belzutifan/lenvatinib or prior vaccine schedule events.; Appraised Oct7 MDAnderson NRG-BR002 investigator report; journal full paper and primary PubMed page inaccessible. Detailed hazard ratios from secondary abstract mirrors are deliberately omitted pending primary access.; BNT122-01 source conflict: Aug28 BioNTech discontinuation/futility/OS-imbalance statement versus Oct7 NCT04486378 active-not-recruiting record with November2026 estimate. Do not infer resumed treatment from registry. Broad cellular/radiopharmaceutical and global oncology census remains incomplete; all treatment-line safety labels not refreshed.

**Informal sources and unresolved claims:** Revisited October2 REGAL any-day event80 speculation and official August11 sponsor release. No new official confirmation of event80 or topline result found in focused searches; retain unconfirmed and do not re-alert. Event accrual cannot identify randomized-arm survival or predict approval. Full investor-call/audio sweep remains incomplete.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT03726879)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT04155749)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT04486378)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT04526106)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT04586231)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT04712097)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT04720157)
- [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT04975308)
- [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT05048797)
- [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT05078866)
- [Source 11](https://clinicaltrials.gov/api/v2/studies/NCT05099172)
- [Source 12](https://clinicaltrials.gov/api/v2/studies/NCT05306340)
- [Source 13](https://clinicaltrials.gov/api/v2/studies/NCT05374512)
- [Source 14](https://clinicaltrials.gov/api/v2/studies/NCT05727904)
- [Source 15](https://clinicaltrials.gov/api/v2/studies/NCT05933577)
- [Source 16](https://clinicaltrials.gov/api/v2/studies/NCT05968326)
- [Source 17](https://clinicaltrials.gov/api/v2/studies/NCT06077760)
- [Source 18](https://clinicaltrials.gov/api/v2/studies/NCT06533579)
- [Source 19](https://clinicaltrials.gov/api/v2/studies/NCT06625320)
- [Source 20](https://clinicaltrials.gov/api/v2/studies/NCT06874335)
- [Source 21](https://clinicaltrials.gov/api/v2/studies/NCT07566052)
- [Source 22](https://clinicaltrials.gov/api/v2/studies?query.term=%28cancer+vaccine+OR+ADC+OR+radiopharmaceutical%29+AND+AREA%5BStudyFirstPostDate%5DRANGE%5B2026-10-02%2C2026-10-09%5D&pageSize=100&format=json)
- [Source 23](https://www.newswise.com/articles/randomized-trial-finds-targeting-individual-metastases-in-oligometastatic-breast-cancer-does-not-improve-survival)
- [Source 24](https://doi.org/10.1200/JCO-26-00201)
- [Source 25](https://clinicaltrials.gov/study/NCT07860047)
- [Source 26](https://clinicaltrials.gov/study/NCT07859592)
- [Source 27](https://clinicaltrials.gov/study/NCT07861425)
- [Source 28](https://clinicaltrials.gov/study/NCT07863024)
- [Source 29](https://ir.sellaslifesciences.com/news/News-Details/2026/SELLAS-Life-Sciences-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Corporate-Update/default.aspx)
- [Source 30](https://www.reddit.com/r/sellasLifescience/comments/1wvlkg6/when_you_add_up_the_dates_below_it_equals_an_80th/)
- [Source 31](https://www.biontech.com/us/en/home/mediaroom/news/statements/2026/08/BioNTech-Provides-Update-on-Phase-2-Clinical-Trial-of-Autogene-Cevumeran-in-Resected-Colorectal-Cancer.html)

### Autoimmune disease and immune reset

**Coverage: focused_incomplete.** 2 newly recorded entries.

**Searches:** Official named-program registry refresh; paginated discovery September 5–October 9, 2026; Dated sponsor, regulator, paper and conference searches; original Reddit and selected podcast/interview leads

**Remaining gaps:** All saved named NCT records refreshed and all pages of official overlap discovery screened (28 returned records). Search starts September 5/6 from the last full successful check, not October 6 alone. Incidental matches excluded; literature, international registries, all regulatory files and complete podcast/audio appraisal remain incomplete.; No matched rap-cel/zola-cel restart announcement verified; pre-pause or unchanged recruiting labels do not prove restart. Full CAR-T longer-term safety, ACR abstract census, FB102 protocol and litifilimab arm-level tables remain gaps.

**Informal sources and unresolved claims:** Read original OncLive September22 discussion of Mount Sinai IBD CAR-T planning; no matched newly initiated study verified, existing stable claim remains unconfirmed. Read lupus/scleroderma Reddit anecdotes and discussions; unverified identity, selected responders and unsupported safety rankings mean no comparative or cure result. Full podcast recordings unreviewed.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT04895696)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT06121297)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT06154252)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT06193889)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT06375993)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT06588491)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT06665256)
- [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT06980805)
- [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT07015983)
- [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT07729826)
- [Source 11](https://clinicaltrials.gov/api/v2/studies/NCT07855302)
- [Source 12](https://clinicaltrials.gov/api/v2/studies?query.term=%28%22CAR+T%22+OR+%22immune+reset%22+OR+fenebrutinib+OR+%22Treg%22%29+AND+%28lupus+OR+myositis+OR+%22multiple+sclerosis%22+OR+%22rheumatoid+arthritis%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json)
- [Source 13](https://argenx.com/news/2026/press-release-3376936.html)
- [Source 14](https://clinicaltrials.gov/study/NCT06982963)
- [Source 15](https://investors.biogen.com/news-releases/news-release-details/biogens-litifilimab-demonstrates-rapid-and-durable-efficacy-new)
- [Source 16](https://clinicaltrials.gov/study/NCT05531565)
- [Source 17](https://www.onclive.com/view/car-t-in-autoimmune-disease-and-key-takeaways)
- [Source 18](https://www.reddit.com/r/lupus/comments/1wsrff5/adicet_bio_cart_sparks_lupus_remissions_in_early/)
- [Source 19](https://www.reddit.com/r/scleroderma/comments/1wurldw/real_treatments_are_coming/)

### Non-opioid pain treatments

**Coverage: focused_incomplete.** 3 newly recorded entries.

**Searches:** Official named-program registry refresh; paginated discovery September 5–October 9, 2026; Dated sponsor, regulator, paper and conference searches; original Reddit and selected podcast/interview leads

**Remaining gaps:** All saved named NCT records refreshed and all pages of official overlap discovery screened (49 returned records). Search starts September 5/6 from the last full successful check, not October 6 alone. Incidental matches excluded; literature, international registries, all regulatory files and complete podcast/audio appraisal remain incomplete.; Broad trial discovery also located NIH experimental-pain HNK and another rotator-cuff suzetrigine study, not promoted as patient efficacy. Full VX-993 and other chronic-pain safety, surgery abstracts and international records remain incompletely appraised.

**Informal sources and unresolved claims:** Read original r/anesthesiology Journavx thread. Anonymous clinician/patient accounts conflict on relief and opioid substitution; mixed regimens, uncontrolled samples and unverified insurance claims are not trial outcomes or reliable coverage estimates. No distinctive formal-development rumor selected; full Radiolab/podcast audio not appraised.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT04570371)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT05273749)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT05553366)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT05558410)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT05661734)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT06628908)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT06696443)
- [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT06797869)
- [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT06887959)
- [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT07231419)
- [Source 11](https://clinicaltrials.gov/api/v2/studies/NCT07856654)
- [Source 12](https://clinicaltrials.gov/api/v2/studies?query.term=%28suzetrigine+OR+%22VX-993%22+OR+onzotrigine+OR+%22LTG321%22+OR+%22non-opioid%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json)
- [Source 13](https://saolrx.com/saol-therapeutics-announces-completion-of-enrollment-in-pivotal-phase-iii-beacon-trial-of-sl1002-for-the-treatment-of-chronic-pain-related-to-osteoarthritis-of-the-knee/)
- [Source 14](https://clinicaltrials.gov/study/NCT07226258)
- [Source 15](https://clinicaltrials.gov/study/NCT06696443)
- [Source 16](https://clinicaltrials.gov/study/NCT07864896)
- [Source 17](https://www.reddit.com/r/anesthesiology/comments/1wqalq7/journavx_suzetrigine/)
- [Source 18](https://clinicaltrials.gov/study/NCT07504601)

### Kidney preservation and earlier detection

**Coverage: focused_incomplete.** 3 newly recorded entries.

**Searches:** ClinicalTrials.gov interventional discovery, LastUpdatePostDate September 5–October 9; updated named records from current topic pages.; Dated official sponsor, regulator, trial/publication, conference and original informal-source searches, with October 7–9 prioritized after the October 6 review.

**Remaining gaps:** Window: September 5–October 9, 2026, retaining the seven-day overlap from the last full successful check on September 12. October 6 findings were deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; Kidney discovery returned 330 records; first 100 downloaded; selected relevant records screened, remainder not completed. Existing REMODEL null primary outcomes, combination registrations and SCD-PED conference milestone retained rather than repeated. Farabursen full registry not reconciled. PYC-003 exact kidney-volume plotted values unavailable numerically; no visual digitization performed.

**Informal sources and unresolved claims:** Original August 9 ADPKD thread, updated October 8, reviewed via indexed comments; Tufts recruitment claim cross-checked at investigator site. Older nephrologist messages are secondhand and conflict on timing. No clinically reliable efficacy inference drawn. Broader kidney podcast/talk transcripts remain incomplete.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT03594110)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT04716231)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT04865770)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT05047263)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT05254002)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT05797610)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT05901831)
- [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT06419205)
- [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT06531824)
- [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT06926660)
- [Source 11](https://clinicaltrials.gov/api/v2/studies/NCT07819227)
- [Source 12](https://clinicaltrials.gov/api/v2/studies/NCT07849348)
- [Source 13](https://clinicaltrials.gov/api/v2/studies/NCT07850752)
- [Source 14](https://clinicaltrials.gov/api/v2/studies/NCT07857200)
- [Source 15](https://clinicaltrials.gov/api/v2/studies?query.term=%28chronic+kidney+disease+OR+IgA+nephropathy+OR+polycystic+kidney+disease%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true)
- [Source 16](https://www.bayer.com/media/en-us/us-fda-accepts-bayers-supplemental-new-drug-application-for-finerenone-in-chronic-kidney-disease-without-diabetes/)
- [Source 17](https://www.bayer.com/en-us/united-states/news-and-stories/2026/kerendia-for-chronic-kidney-disease)
- [Source 18](https://app.sharelinktechnologies.com/announcement/asx/4013a49b3a4dd2ccf036ca460eb13793)
- [Source 19](https://www.asn-online.org/education/kidneyweek/2026/program-abstract.aspx?controlId=4559428)
- [Source 20](https://clinicaltrials.gov/study/NCT06714006)
- [Source 21](https://www.tuftsmedicine.org/research-clinical-trials/find-clinical-trials/novartis-ccyx082a12301-study)
- [Source 22](https://www.reddit.com/r/ADPKD/comments/1vjuvrx/any_updates_about_farabursen_phase_3_trials/)

### Hearing and vision preservation/restoration

**Coverage: focused_incomplete.** 1 newly recorded entries.

**Searches:** EURETINA October2026 retinal late breaking BEST1 MCO010 PST611 results; 4SIGHT 4D150 October2026 SPECTRA phase3; site:reddit.com AC102 October2026 hearing trial; hearing loss macular degeneration retinal gene therapy newly registered October2–9 2026

**Remaining gaps:** Read current topic/state and September5 overlap. All13 saved registry records plus10 newly registered matches retrieved. Recovered Sept28 4DMT primary release, corroborated new Oct9 4SIGHT record; no duplicate PRIMA36month or MOGENRY priority-review announcements.; Official EURETINA final-session/late-breaking reporting opened. New 4D150 DME findings have primary sponsor counts; PST611 qualitative summary is not an exact efficacy table. PRIMA conference-summary threshold differs from sponsor release and was not silently substituted.; BEST1 fullPDF retried through web and direct network, still403. Actual MCO010 acquired GA tables/trial match, PST611 tables and full DAYBREAK/BRUNELLO safety intervals remain gaps. Hearing acquired-loss inventory not fully refreshed.

**Informal sources and unresolved claims:** Original Oct2 investigator interview by ArshadKhanani discusses SPECTRA/4SIGHT, corroborating the public sponsor development announcement, not proving larger-trial safety. AC102 purported August29 email claim remains unconfirmed; live NCT05776459 retains January16 snapshot with elapsed February/July completion estimates, no posted results. No phase3/tinnitus launch inferred. Wider podcast sweep incomplete.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT04676854)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT04919473)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT04945772)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT05417126)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT05776459)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT05788536)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT06556368)
- [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT06571045)
- [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT07024732)
- [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT07032038)
- [Source 11](https://clinicaltrials.gov/api/v2/studies/NCT07185256)
- [Source 12](https://clinicaltrials.gov/api/v2/studies/NCT07812090)
- [Source 13](https://clinicaltrials.gov/api/v2/studies/NCT07826507)
- [Source 14](https://clinicaltrials.gov/api/v2/studies?query.term=%28hearing+loss+OR+macular+degeneration+OR+retinal+gene+therapy%29+AND+AREA%5BStudyFirstPostDate%5DRANGE%5B2026-10-02%2C2026-10-09%5D&pageSize=100&format=json)
- [Source 15](https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-advances-4d-150-phase-3-second-large-market-retina)
- [Source 16](https://clinicaltrials.gov/study/NCT07867080)
- [Source 17](https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4dmt-host-investor-day-october-21-2026)
- [Source 18](https://euretinacongressdaily.org/frontiers-in-retinal-innovation-late-breaking-trial-results-highlight-gene-therapies-subretinal-implants-and-extended-delivery-in-namd-and-ga/)
- [Source 19](https://www.ophthalmologytimes.com/view/euretina-2026-2-year-spectra-results-and-the-phase-3-programme-for-4d-150-gene-therapy-in-dmo)
- [Source 20](https://www.reddit.com/r/tinnitusresearch/comments/1w1vebv/audiocure_ac102_update/)
- [Source 21](https://ir.opusgtx.com/presentations)

### Hair loss, restoration and graying

**Coverage: focused_incomplete.** 3 newly recorded entries.

**Searches:** hair_loss: named programs and broader human-study discovery, September 5–October 9, with priority to October 6–9.; hair_loss: original Reddit posts, podcast/talk descriptions and unresolved saved informal claims.; Europe PMC FIRST_PDATE September 5–October 9 failed HTTP503; targeted web primary literature used as partial fallback.

**Remaining gaps:** Read the current assigned topic and canonical scope/state. Named original registry records refreshed; all pages of broad ClinicalTrials.gov discovery for September 5–October 9 were retrieved (200 records, with incidental matches excluded). This honors the seven-day overlap from the saved September 12 full successful check.; Europe PMC original-literature discovery again returned HTTP 503. Targeted primary publisher, sponsor and conference searches were performed, but the worldwide paper/regulator/procedure and original-audio census remains incomplete. Preserve last_successful_check_utc.; AWAKEN October 7 changes did not alter the saved recruitment/start/phase/size milestones, so no duplicate recruitment alert. Clascoterone, HEADLINE, VDPHL01, GT20029 and BioCopper named records retain status. Full current Kintor/Veradermics global guidance, every AA regulator/label and rare-harm census incomplete.; New Olistic retrospective female-pattern-hair-loss NCT07862374 and telogen-effluvium NCT07869199 are planned/review records without outcomes, with retrospective design but future registry schedule; not promoted as randomized benefit. FB102 October 8 celiac release is owned by autoimmune; vitiligo/AA references do not add a new hair result.

**Informal sources and unresolved claims:** Reopened BioQ and original ToastedCaffeine Reddit post: BQ-002 existence is corroborated, but candidate-specific human trial and 2027 start remain unconfirmed. Cosmo still forecasts Q1 2027 U.S. filing, not launch; saved late-2027/2028 community inference is unchanged. October 6 PP405 https://www.reddit.com/r/tressless/comments/1wz35hi/pp405_phase_23_study_has_begun/ repeats a saved registry milestone. October 9 pipeline hopes https://www.reddit.com/r/tressless/comments/1x1fxgm/are_you_hopeful_for_the_potential_future/ add speculative timing, not a new attributable formal event. No repeat rumor alert. Full audio/transcripts incomplete.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT03811912)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT05910450)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT05914805)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT06018428)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT06393452)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT06692465)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT06724614)
- [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT06972264)
- [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT07317544)
- [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT07484061)
- [Source 11](https://clinicaltrials.gov/api/v2/studies/NCT07810504)
- [Source 12](https://clinicaltrials.gov/api/v2/studies/NCT07819435)
- [Source 13](https://clinicaltrials.gov/api/v2/studies/NCT07839494)
- [Source 14](https://clinicaltrials.gov/api/v2/studies?query.term=%28alopecia+OR+graying+OR+greying+OR+PP405+OR+ABS-201+OR+KX-826+OR+clascoterone+OR+VDPHL01%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json)
- [Source 15](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%28alopecia+OR+graying+OR+greying%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-09%5D&format=json&pageSize=100&resultType=core&sort=FIRST_PDATE_D)
- [Source 16](https://lillyscience.lilly.com/download/GXHSMnoBQkYc7swUY1k2Q)
- [Source 17](https://www.lilly.com/hcp/congresses/fall-clinical-2026)
- [Source 18](https://clinicaltrials.gov/study/NCT06393452)
- [Source 19](https://clinicaltrials.gov/study/NCT07819435)
- [Source 20](https://clinicaltrials.gov/study/NCT07863856)
- [Source 21](https://www.bioq.com/)
- [Source 22](https://www.reddit.com/r/greyhairreversal/comments/1t0k55l/bioq_is_developing_an_injectable_drug_bq002/)
- [Source 23](https://www.cosmohealthconfidence.com/news/64300770-h1-2026)
- [Source 24](https://pelagepharma.com/press-releases/)

### Skin aging, laxity and regeneration

**Coverage: focused_incomplete.** 1 newly recorded entries.

**Searches:** skin_aging: named programs and broader human-study discovery, September 5–October 9, with priority to October 6–9.; skin_aging: original Reddit posts, podcast/talk descriptions and unresolved saved informal claims.; Europe PMC FIRST_PDATE September 5–October 9 failed HTTP503; targeted web primary literature used as partial fallback.

**Remaining gaps:** Read the current assigned topic and canonical scope/state. Named original registry records refreshed; all pages of broad ClinicalTrials.gov discovery for September 5–October 9 were retrieved (41 records, with incidental matches excluded). This honors the seven-day overlap from the saved September 12 full successful check.; Europe PMC original-literature discovery again returned HTTP 503. Targeted primary publisher, sponsor and conference searches were performed, but the worldwide paper/regulator/procedure and original-audio census remains incomplete. Preserve last_successful_check_utc.; KB304 remains active/not recruiting with stale 2025 completion estimate; no Phase 2 actual initiation verified. Ellacor nine-person completed/no-results cohort and AnteAGE pilot registrations already captured October 6. FDA RF-microneedling communication remains older ongoing evaluation, not relabeled a new alert.; Sofwave June paper full text redirected to abstract; October 5 sponsor promotion deduplicated by actual paper date. September 22 multimodal RF RCT full appraisal and world device clearance/rare-complication census remain incomplete. PRX S acne-prone skin NCT07866131 is an observational cosmetic protocol, no outcome.

**Informal sources and unresolved claims:** October 6 Vitality Unfiltered David Bauder/Alicia Sanderson episode https://www.buzzsprout.com/2542776/episodes/19774930-sofwave-non-surgical-skin-tightening-collagen-facial-rejuvenation-with-alicia-sanderson-md?t=0 was found as original show description. It concerns existing procedures, not a verified new trial milestone; full audio/transcript not reviewed. Earlier Lufkin/Durairaj rapalog/GLP-1-face lead remains unappraised. No new rumor selected.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT06477172)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT06724900)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT07224880)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT07661004)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT07790237)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT07849205)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT07849556)
- [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT07853027)
- [Source 9](https://clinicaltrials.gov/api/v2/studies?query.term=%28skin+AND+%28rejuvenation+OR+laxity+OR+wrinkles%29%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json)
- [Source 10](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%28%28skin+AND+%28rejuvenation+OR+laxity+OR+wrinkles%29%29+AND+%28trial+OR+prospective+OR+comparative%29%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-09%5D&format=json&pageSize=100&resultType=core&sort=FIRST_PDATE_D)
- [Source 11](https://onlinelibrary.wiley.com/doi/10.1002/lsm.70153)
- [Source 12](https://sofwave.com/news/new-peer-reviewed-study-shows-sustained-improvement-in-skin-laxity-through-nine-months-after-a-single-sofwave-treatment-in-asian-patients)

### Scar prevention, treatment and stretch marks

**Coverage: focused_incomplete.** 2 newly recorded entries.

**Searches:** scars: named programs and broader human-study discovery, September 5–October 9, with priority to October 6–9.; scars: original Reddit posts, podcast/talk descriptions and unresolved saved informal claims.; Europe PMC FIRST_PDATE September 5–October 9 failed HTTP503; targeted web primary literature used as partial fallback.

**Remaining gaps:** Read the current assigned topic and canonical scope/state. Named original registry records refreshed; all pages of broad ClinicalTrials.gov discovery for September 5–October 9 were retrieved (182 records, with incidental matches excluded). This honors the seven-day overlap from the saved September 12 full successful check.; Europe PMC original-literature discovery again returned HTTP 503. Targeted primary publisher, sponsor and conference searches were performed, but the worldwide paper/regulator/procedure and original-audio census remains incomplete. Preserve last_successful_check_utc.; SCARFREE still not yet recruiting, with October 2026/August–November 2028 estimates already captured. Geneva verteporfin and siSPARC remain stale/not-yet-recruiting or unknown. October 1 Syntara expansion and local-reaction/null clinical findings were deduplicated.; New October 3 CO2-versus-microplasma-RF hypertrophic-scar abstract PMID42828438 has domain-specific short-term changes but lacks participant count and co-primary score effects; full paper appraisal remains a gap, no broad efficacy/zero-harm claim. October 9 retrospective disclosure NCT07868445 lists a completed 30-person laser/exosome-versus-HA acne-scar study with June–September 2025 dates and no posted results; narrative superiority wording was not treated as an outcome table. Full stretch-mark and rare-harm census incomplete.

**Informal sources and unresolved claims:** Saved August26 r/verteporfin https://www.reddit.com/r/verteporfin/comments/1vypnsk/verteporfin_status_upcoming_trials_and/ and recent formal-trial searches found no new documented dosing/efficacy claim. Unregulated/off-label self-experimentation and anecdotes were not converted into trial outcomes. Full investor recordings and podcast originals incomplete; no new rumor selected.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT02070809)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT05461755)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT06033430)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT06138964)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT06944249)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT07488988)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT07849010)
- [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT07850557)
- [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT07854470)
- [Source 10](https://clinicaltrials.gov/api/v2/studies?query.term=%28scar+OR+keloid+OR+striae+OR+stretchmark+OR+verteporfin%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json)
- [Source 11](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%28%28scar+OR+keloid+OR+striae+OR+stretchmark%29+AND+%28trial+OR+prospective+OR+comparative%29%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-09%5D&format=json&pageSize=100&resultType=core&sort=FIRST_PDATE_D)
- [Source 12](https://www.nature.com/articles/s41598-026-72854-8)
- [Source 13](https://link.springer.com/article/10.1007/s10103-026-05026-9)
- [Source 14](https://pubmed.ncbi.nlm.nih.gov/42828438/)
- [Source 15](https://clinicaltrials.gov/study/NCT07868445)
- [Source 16](https://www.reddit.com/r/verteporfin/comments/1vypnsk/verteporfin_status_upcoming_trials_and/)

### Facial volume restoration and contour

**Coverage: focused_incomplete.** 1 newly recorded entries.

**Searches:** facial_volume: named programs and broader human-study discovery, September 5–October 9, with priority to October 6–9.; facial_volume: original Reddit posts, podcast/talk descriptions and unresolved saved informal claims.; Europe PMC FIRST_PDATE September 5–October 9 failed HTTP503; targeted web primary literature used as partial fallback.

**Remaining gaps:** Read the current assigned topic and canonical scope/state. Named original registry records refreshed; all pages of broad ClinicalTrials.gov discovery for September 5–October 9 were retrieved (107 records, with incidental matches excluded). This honors the seven-day overlap from the saved September 12 full successful check.; Europe PMC original-literature discovery again returned HTTP 503. Targeted primary publisher, sponsor and conference searches were performed, but the worldwide paper/regulator/procedure and original-audio census remains incomplete. Preserve last_successful_check_utc.; Macrofat NCT07805889 recruiting 400 and GLP1-Radiesse recruiting/no results retain status. HArmonyCa completion and new Facetem/Radiesse registrations already recorded October 6. No new comparative efficacy selected.; Full new-filler FDA/overseas inventory, precise launch inventory, rare delayed harms and post-weight-loss randomized efficacy remain incomplete. Existing HA-collagen reporting discrepancy not resolved.

**Informal sources and unresolved claims:** October9 https://www.reddit.com/r/PlasticSurgery/comments/1x1lv4i/fat_grafting_failed_renuva_vs_sculptra_for/ describes personal graft-survival experience and requests alternatives; not a formal trial or general incidence. Recent Secret Services podcast descriptions and saved Lufkin/Durairaj episode do not supply a verified new named-program claim; recordings/transcripts not appraised. Adipeau promotion remains distinct from its already saved uncontrolled pilot. No new rumor selected.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT04769193)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT06351358)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT07032597)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT07419854)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT07805889)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT07855224)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT07856797)
- [Source 8](https://clinicaltrials.gov/api/v2/studies?query.term=%28%28facial+AND+%28filler+OR+volume+OR+fat%29%29+OR+Radiesse+OR+HarmonyCa+OR+Facetem%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json)
- [Source 9](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%28%28facial+AND+%28filler+OR+volume+OR+fat%29%29+AND+%28trial+OR+prospective+OR+comparative%29%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-09%5D&format=json&pageSize=100&resultType=core&sort=FIRST_PDATE_D)
- [Source 10](https://us.merzaesthetics.com/news/merz-aesthetics-brings-belotero-hap-to-us-market-fda-approvals-belo-volume-belo-intense/)
- [Source 11](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P250016)
- [Source 12](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P250020)

### Pigmentation and uneven skin tone

**Coverage: focused_incomplete.** 1 newly recorded entries.

**Searches:** pigmentation: named programs and broader human-study discovery, September 5–October 9, with priority to October 6–9.; pigmentation: original Reddit posts, podcast/talk descriptions and unresolved saved informal claims.; Europe PMC FIRST_PDATE September 5–October 9 failed HTTP503; targeted web primary literature used as partial fallback.

**Remaining gaps:** Read the current assigned topic and canonical scope/state. Named original registry records refreshed; all pages of broad ClinicalTrials.gov discovery for September 5–October 9 were retrieved (53 records, with incidental matches excluded). This honors the seven-day overlap from the saved September 12 full successful check.; Europe PMC original-literature discovery again returned HTTP 503. Targeted primary publisher, sponsor and conference searches were performed, but the worldwide paper/regulator/procedure and original-audio census remains incomplete. Preserve last_successful_check_utc.; STOP-V1/V2, DelVito and FXS5626 saved status retained; no new registry results. October 1 Viti-Up extension/phototherapy sponsor data deduplicated. Incyte actual EADV P2467/P1780/P2463 posters remain a retrieval gap.; No full melasma/PIH/solar-lentigine trial or regulator census. KT939 matched protocol/current cosmetic submission status still unresolved. October 8 maturational-hyperpigmentation characterization is not a treatment readout.

**Informal sources and unresolved claims:** October7 https://www.reddit.com/r/Vitiligo/comments/1x01ejq/11_yr_old_daughter_with_vitiligo_question_about/ includes an anonymous long-term povorcitinib participant anecdote and generalized safety assertions, not blinded outcome data or approval confirmation. October6 r/Scholar request for a 2025 tranexamic-acid review is a repost/access request, not fresh data. Saved melasma podcast remains descriptive with no new attributable forecast; full audio not reviewed.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT03926845)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT04052425)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT04057573)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT06113445)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT06113471)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT06118411)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT07820098)
- [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT07840820)
- [Source 9](https://clinicaltrials.gov/api/v2/studies?query.term=%28melasma+OR+vitiligo+OR+hyperpigmentation%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json)
- [Source 10](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%28%28melasma+OR+vitiligo+OR+hyperpigmentation%29+AND+%28trial+OR+prospective+OR+comparative%29%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-09%5D&format=json&pageSize=100&resultType=core&sort=FIRST_PDATE_D)
- [Source 11](https://clinicaltrials.gov/study/NCT07865312)

### Acne and rosacea

**Coverage: focused_incomplete.** 2 newly recorded entries.

**Searches:** acne_rosacea: named programs and broader human-study discovery, September 5–October 9, with priority to October 6–9.; acne_rosacea: original Reddit posts, podcast/talk descriptions and unresolved saved informal claims.; Europe PMC FIRST_PDATE September 5–October 9 failed HTTP503; targeted web primary literature used as partial fallback.

**Remaining gaps:** Read the current assigned topic and canonical scope/state. Named original registry records refreshed; all pages of broad ClinicalTrials.gov discovery for September 5–October 9 were retrieved (52 records, with incidental matches excluded). This honors the seven-day overlap from the saved September 12 full successful check.; Europe PMC original-literature discovery again returned HTTP 503. Targeted primary publisher, sponsor and conference searches were performed, but the worldwide paper/regulator/procedure and original-audio census remains incomplete. Preserve last_successful_check_utc.; SP0268 vaccine, remibrutinib PPR and redness-study records refreshed; no new posted outcomes. Denifanstat Chinese extension already reported September 30 and not treated as a new Oct9 efficacy result.; New PRX S observational cosmetic record NCT07866131 and retrospective exosome-acne-scar disclosure noted without efficacy inference; scar repair belongs to scars. Full rosacea ocular/flushing/vessel and antibiotic-resistance/label/device census incomplete. Sagimet full October9 release blocked403, indexed primary clinical-development wording checked against complete registry.

**Informal sources and unresolved claims:** Targeted October6–9 Reddit and original talk/podcast queries did not recover a noteworthy new AURORA/B244/SP0268 rumor. Sagimet Fall Clinical/replay descriptions are sponsor context, not full Q&A verification. Earlier UK Finacea shortage anecdote was not generalized to U.S. availability; no manufacturer confirmation. Full recorded discussions incomplete.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT05296629)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT05343455)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT06090721)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT06248008)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT06316297)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT06952517)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT07521462)
- [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT07681271)
- [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT07805655)
- [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT07854418)
- [Source 11](https://clinicaltrials.gov/api/v2/studies?query.term=%28acne+OR+rosacea+OR+denifanstat%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json)
- [Source 12](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%28%28acne+OR+rosacea%29+AND+%28trial+OR+prospective+OR+comparative%29%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-09%5D&format=json&pageSize=100&resultType=core&sort=FIRST_PDATE_D)
- [Source 13](https://clinicaltrials.gov/study/NCT07863193)
- [Source 14](https://www.globenewswire.com/news-release/2026/10/09/3377993/0/en/sagimet-to-present-positive-full-52-week-results-from-license-partner-ascletis-phase-3-open-label-extension-clinical-trial-of-denifanstat-in-acne-and-mechanistic-data-at-the-2026-f.html)
- [Source 15](https://clinicaltrials.gov/study/NCT07866105)
- [Source 16](https://www.aobiome.com/press/press-releases/?y=2026)

### Dental alignment, regeneration and repair

**Coverage: focused_incomplete.** 1 newly recorded entries.

**Searches:** dental: named programs and broader human-study discovery, September 5–October 9, with priority to October 6–9.; dental: original Reddit posts, podcast/talk descriptions and unresolved saved informal claims.; Europe PMC FIRST_PDATE September 5–October 9 failed HTTP503; targeted web primary literature used as partial fallback.

**Remaining gaps:** Read the current assigned topic and canonical scope/state. Named original registry records refreshed; all pages of broad ClinicalTrials.gov discovery for September 5–October 9 were retrieved (288 records, with incidental matches excluded). This honors the seven-day overlap from the saved September 12 full successful check.; Europe PMC original-literature discovery again returned HTTP 503. Targeted primary publisher, sponsor and conference searches were performed, but the worldwide paper/regulator/procedure and original-audio census remains incomplete. Preserve last_successful_check_utc.; P11-4 official abstract https://sciforum.net/paper/34045 remains the same October2 material already appraised; conference October7–9 does not prove extra results or actual delivery. Direct printed-aligner September24 publication and registry status deduplicated. NCT07496892 still not yet recruiting with stale elapsed estimates; OrthoPulse status unchanged.; Toregem news now has October6 BioJapan business presence but no PhaseIIa first dosing/results verification. Japanese original jRCT matched PhaseIIa and complete PhaseI numerical safety remain unresolved. Numerous new October6–9 retrospective/historical bracket-bonding, mouthrinse, pulpotomy and movement records lack outcomes; their registration was not relabeled as new demonstrated clinical benefit. Full alignment/root/gum/final-bite/retention and new-tooth/repair census remains incomplete.

**Informal sources and unresolved claims:** Saved https://www.reddit.com/r/Biohackers/comments/1wq1adh/910_dentists_probably_wont_recommend_this/ and October4 https://www.reddit.com/r/ITOI/comments/1wxkmlv/japan_is_trialing_a_drug_that_regrows_human_teeth/ repeat older TRG035/2030 expectations and extrapolate to acquired missing teeth. No new controlled human result or verified phaseIIa dose followed. Fresh comment activity is not independent confirmation. No new rumor selected; full orthodontic/tooth-regrowth recordings not appraised.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT02954133)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT05213338)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT05361616)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT06685029)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT06749977)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT06881615)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT07496892)
- [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT07638397)
- [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT07842120)
- [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT07859358)
- [Source 11](https://clinicaltrials.gov/api/v2/studies?query.term=%28orthodontic+OR+aligner+OR+braces+OR+enamel+OR+periodontal+OR+toothregeneration+OR+TRG035%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json)
- [Source 12](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%28%28orthodontic+OR+aligner+OR+braces+OR+enamel+OR+periodontal+OR+toothregeneration+OR+TRG035%29+AND+%28trial+OR+prospective+OR+comparative%29%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-09%5D&format=json&pageSize=100&resultType=core&sort=FIRST_PDATE_D)
- [Source 13](https://clinicaltrials.gov/study/NCT07867067)
- [Source 14](https://sciforum.net/paper/34045)
- [Source 15](https://toregem.co.jp/en/news)

### Allergy and airway disease

**Coverage: focused_incomplete.** 1 newly recorded entries.

**Searches:** Official named-program registry refresh; paginated discovery September 5–October 9, 2026; Dated sponsor, regulator, paper and conference searches; original Reddit and selected podcast/interview leads

**Remaining gaps:** All saved named NCT records refreshed and all pages of official overlap discovery screened (131 returned records). Search starts September 5/6 from the last full successful check, not October 6 alone. Incidental matches excluded; literature, international registries, all regulatory files and complete podcast/audio appraisal remain incomplete.; No fuller rademikibart acute-COPD absolute-count/CI/harms table or verified VIASKIN filing acceptance/action date recovered. Food/environmental allergy and sinus literature remain incomplete; no approval inferred from submission.

**Informal sources and unresolved claims:** Reddit rademikibart/VIASKIN and allergy podcast discovery mainly surfaced known sponsor readout/submission reposts and personal treatment experience. No independent new development rumor selected. Original conference audio and broader seasonal/sinus informal survey remain unappraised.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT03881696)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT04851964)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT05158387)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT05166889)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT05276570)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT05741476)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT06940141)
- [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT06940154)
- [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT07241546)
- [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT07675811)
- [Source 11](https://clinicaltrials.gov/api/v2/studies/NCT07858123)
- [Source 12](https://clinicaltrials.gov/api/v2/studies?query.term=%28asthma+OR+COPD+OR+%22food+allergy%22+OR+%22chronic+sinusitis%22%29+AND+%28%22PHASE2%22+OR+%22PHASE3%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json)
- [Source 13](https://clinicaltrials.gov/study/NCT07869043)
- [Source 14](https://www.pfizer.com/news/press-release/press-release-detail/pfizers-tilrekimig-shows-significant-skin-clearance-phase-2)
- [Source 15](https://investors.connectbiopharma.com/news-releases/news-release-details/connect-biopharma-announces-positive-preliminary-topline-data-0/)
- [Source 16](https://www.globenewswire.com/news-release/2026/09/29/3371452/0/en/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years.html)

### Infectious-disease prevention and treatment

**Coverage: focused_incomplete.** 1 newly recorded entries.

**Searches:** Official named-program registry refresh; paginated discovery September 5–October 9, 2026; Dated sponsor, regulator, paper and conference searches; original Reddit and selected podcast/interview leads

**Remaining gaps:** All saved named NCT records refreshed and all pages of official overlap discovery screened (312 returned records). Search starts September 5/6 from the last full successful check, not October 6 alone. Incidental matches excluded; literature, international registries, all regulatory files and complete podcast/audio appraisal remain incomplete.; VAX-31 topline and earlier PLG0206/China RSV/TNP2092 events already saved and deduplicated. No actual STEPS-CF first dosing verified. Broader new-antibiotic human efficacy, regulator files, conference abstracts and long-acting infection-prevention census remain incomplete. Gepotidacin resistance paper has September 1 online date despite October issue; not relabeled new October news.

**Informal sources and unresolved claims:** Located Communicable E64 (October4, Emily McDonald/Marc Bonten with Sylvain Lother/Valentijn Schweitzer) and Children’s Colorado Charting Pediatrics October6 show notes. These discuss existing antibiotic evidence/ stewardship rather than a new-development claim; full audio unreviewed. Read original personalized-phage-guideline Reddit discussion; expert consensus is not randomized efficacy. No separate noteworthy new rumor selected.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT03806166)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT03959527)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT04979806)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT05184764)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT06602024)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT07047716)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT07214311)
- [Source 8](https://clinicaltrials.gov/api/v2/studies/NCT07284654)
- [Source 9](https://clinicaltrials.gov/api/v2/studies/NCT07298434)
- [Source 10](https://clinicaltrials.gov/api/v2/studies/NCT07326540)
- [Source 11](https://clinicaltrials.gov/api/v2/studies/NCT07431307)
- [Source 12](https://clinicaltrials.gov/api/v2/studies/NCT07655180)
- [Source 13](https://clinicaltrials.gov/api/v2/studies/NCT07858916)
- [Source 14](https://clinicaltrials.gov/api/v2/studies/NCT07860216)
- [Source 15](https://clinicaltrials.gov/api/v2/studies?query.term=%28antibiotic+OR+bacteriophage+OR+vaccine+OR+antiviral%29+AND+%28%22PHASE2%22+OR+%22PHASE3%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json)
- [Source 16](https://clinicaltrials.gov/study/NCT07863401)
- [Source 17](https://podcasts.apple.com/ie/podcast/communicable-e64-getting-micro-on-macrolides-for-community/id1745730614?i=1000793146688)
- [Source 18](https://www.childrenscolorado.org/health-professionals/publications/charting-pediatrics-podcast/reducing-prescriptions-with-acute-otitis-media/)
- [Source 19](https://www.reddit.com/r/microbiomenews/comments/1wp1546/over_60_new_rules_from_20_medical_groups_now/)
- [Source 20](https://pubmed.ncbi.nlm.nih.gov/42682990/)

### Genetic screening and risk prediction

**Coverage: focused_incomplete.** 2 newly recorded entries.

**Searches:** Universal germline genetic testing cancer October8 2026 Stadler 39184; genomic screening polygenic pharmacogenomic embryo selection newly registered September6 October9 2026; site:mynucleus.com Vitruvian October2026 trialresults; site:reddit.com genetic screening October2026

**Remaining gaps:** Read current topic/state and September6 overlap. All seven saved registries and new-registration discovery retrieved. PGT-P NCT07841769 remains not yet recruiting in Sept25 record after its Oct1 estimated start; actual start unverified.; Appraised official Oct8 AACR/MSK germline-study reports and Oct6 Yale planned prospective project. Primary germline full paper failed403; PubMed unavailable and EuropePMC not yet indexed. Do not claim full paper/supplement appraisal.; PGT-M/SR/A guidance, newborn genomic screening and pharmacogenomics were not comprehensively refreshed. New FOCUS Sept8 population-genomic implementation registry was located, but inconsistent site/sample counts require detailed follow-up before promoting it.

**Informal sources and unresolved claims:** Revisited original Nucleus/Vitruvian source chain and sponsor September whitepaper. Five-embryo top-versus-bottom10.8IQ and ten-embryo14.3IQ are model projections with predominantly European-ancestry sibling validation; not observed offspring outcomes or top-versus-average gain. Original X remains inaccessible. No new confirmation/retraction found; leave existing rumor unconfirmed without repeat alert.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT02620852)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT03093818)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT03857477)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT04339166)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT07051213)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT07802496)
- [Source 7](https://clinicaltrials.gov/api/v2/studies/NCT07841769)
- [Source 8](https://clinicaltrials.gov/api/v2/studies?query.term=%28genomic+screening+OR+polygenic+OR+pharmacogenomic+OR+embryo+selection%29+AND+AREA%5BStudyFirstPostDate%5DRANGE%5B2026-09-06%2C2026-10-09%5D&pageSize=100&format=json)
- [Source 9](https://www.aacr.org/about-the-aacr/newsroom/news-releases/current-age-based-genetic-testing-in-patients-with-cancer-may-miss-majority-of-inherited-gene-variants/)
- [Source 10](https://doi.org/10.1158/2159-8290.CD-26-0971)
- [Source 11](https://www.mskcc.org/news/study-suggests-every-cancer-patient-should-be-tested-for-inherited-cancer-mutations)
- [Source 12](https://medicine.yale.edu/news-article/yale-pilots-genomic-screening-through-primary-care/)
- [Source 13](https://popgenscreening.org/)
- [Source 14](https://mynucleus.com/labs/traits-whitepaper)
- [Source 15](https://www.reddit.com/r/singularity/comments/1wrq633/introducing_vitruvian_a_genetic_optimization/)
- [Source 16](https://x.com/KianSadeghi5/status/2101018839412531231)

### Insomnia

**Coverage: focused_incomplete.** 1 newly recorded entries.

**Searches:** ClinicalTrials.gov interventional discovery, LastUpdatePostDate September 5–October 9; updated named records from current topic pages.; Dated official sponsor, regulator, trial/publication, conference and original informal-source searches, with October 7–9 prioritized after the October 6 review.

**Remaining gaps:** New condition baseline remains incomplete. Reviewed inherited hub, preceding 90-day development leads and selected older pivotal/contextual sources; October 6 findings deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; Broad insomnia discovery returned 673 records, first 100 downloaded; selected relevant records screened; much incidental oncology/psychiatry symptom language remains. Older drug label, CBT-I/digital durability and sleep-architecture safety census incomplete. Prior DARI-DREAM and COMISA-PEC not re-reported.

**Informal sources and unresolved claims:** Oct8 SOLIS-1 participant self-report and Oct2 Eloralintide weekly-trial posts contain insomnia/fatigue anecdotes; no population safety estimates or independent insomnia-drug milestone inferred. Original insomnia podcast/talk transcripts incomplete.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT05423717)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT06823752)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT07743931)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT07843329)
- [Source 5](https://clinicaltrials.gov/api/v2/studies?query.term=%28insomnia%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true)
- [Source 6](https://clinicaltrials.gov/study/NCT07542756)

### Obstructive sleep apnea

**Coverage: focused_incomplete.** 2 newly recorded entries.

**Searches:** ClinicalTrials.gov interventional discovery, LastUpdatePostDate September 5–October 9; updated named records from current topic pages.; Dated official sponsor, regulator, trial/publication, conference and original informal-source searches, with October 7–9 prioritized after the October 6 review.

**Remaining gaps:** New condition baseline remains incomplete. Reviewed inherited hub, preceding 90-day development leads and selected older pivotal/contextual sources; October 6 findings deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; All 66 matches in the bounded OSA discovery were downloaded; selected relevant records screened, plus saved registries. It is not a full older PAP/oral-appliance/surgical/device-validation baseline. Sleep outcomes versus cardiovascular outcomes retained separately.

**Informal sources and unresolved claims:** Targeted apnea drug/device rumor searches did not yield a new original development claim promoted in this bounded review. Full Oct2 AADSM podcast recording and older device-access/insurance anecdotes not appraised.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT04153240)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT05813275)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT07225686)
- [Source 4](https://clinicaltrials.gov/api/v2/studies?query.term=%28obstructive+sleep+apnea%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true)
- [Source 5](https://clinicaltrials.gov/study/NCT07846865)
- [Source 6](https://clinicaltrials.gov/study/NCT07823608)

### Narcolepsy & excessive sleepiness

**Coverage: focused_incomplete.** 1 newly recorded entries.

**Searches:** ClinicalTrials.gov interventional discovery, LastUpdatePostDate September 5–October 9; updated named records from current topic pages.; Dated official sponsor, regulator, trial/publication, conference and original informal-source searches, with October 7–9 prioritized after the October 6 review.

**Remaining gaps:** New condition baseline remains incomplete. Reviewed inherited hub, preceding 90-day development leads and selected older pivotal/contextual sources; October 6 findings deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; All 13 matches in the bounded hypersomnolence discovery downloaded; selected relevant records screened. Saved orexin protocols refreshed. Established oxybate/stimulant/pitolisant/solriamfetol full labeling/safety and whole-world baseline remain incomplete.; Official Orzeyful page retains expected-by-November availability conditional on DEA scheduling. No completed official DEA scheduling action established; do not imply launch.

**Informal sources and unresolved claims:** Original Oct7 r/Narcolepsy thread contains anonymous patient participation in an orexin trial, not a new official recruitment/readout milestone. Sponsor conditional Orzeyful forecast checked; full talk/audio not reviewed.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT06752668)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT06812078)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT06843590)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT06952699)
- [Source 5](https://clinicaltrials.gov/api/v2/studies/NCT07598708)
- [Source 6](https://clinicaltrials.gov/api/v2/studies/NCT07646678)
- [Source 7](https://clinicaltrials.gov/api/v2/studies?query.term=%28narcolepsy+OR+idiopathic+hypersomnia%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true)
- [Source 8](https://clinicaltrials.gov/study/NCT07625280)
- [Source 9](https://www.orzeyful.com/)
- [Source 10](https://www.reddit.com/r/Narcolepsy/comments/1wzuxbd/what_is_the_treatment_for_narcolepsy_without/)

### Circadian rhythm disorders

**Coverage: focused_incomplete.** 0 newly recorded entries.

**Searches:** ClinicalTrials.gov interventional discovery, LastUpdatePostDate September 5–October 9; updated named records from current topic pages.; Dated official sponsor, regulator, trial/publication, conference and original informal-source searches, with October 7–9 prioritized after the October 6 review.

**Remaining gaps:** New condition baseline remains incomplete. Reviewed inherited hub, preceding 90-day development leads and selected older pivotal/contextual sources; October 6 findings deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; Circadian broad query returned 154 records; first 100 downloaded; selected relevant records screened, remainder incomplete, with many incidental/mechanistic and oncology timing matches. Timed light/dark and melatonin disorder-specific sustained phase/function baseline remains incomplete.; Tasimelteon jet-lag hearing outcome/date not verified. Searches still locate June 3 notice and elapsed July 20 prehearing plan; no conclusion inferred. Saved DSWPD and SUSTAIN registry milestones preserved as estimates; no new result found in those specific records.

**Informal sources and unresolved claims:** Original October 2 r/DSPD discussion and October4/5 comments reviewed through indexed text: individual timing/medicine/light experiences, no attributable new formal trial result or development leak. No broad efficacy conclusion from anecdotes; full podcast/talk appraisal remains incomplete.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT03715465)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT04652882)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT06568367)
- [Source 4](https://clinicaltrials.gov/api/v2/studies?query.term=%28circadian+OR+shift+work+disorder+OR+delayed+sleep+wake%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true)
- [Source 5](https://www.govinfo.gov/content/pkg/FR-2026-06-03/pdf/2026-11046.pdf)
- [Source 6](https://www.reddit.com/r/DSPD/comments/1wvt487/anyone_found_a_cure_or_something_that_works_long/)

### Restless legs syndrome

**Coverage: focused_incomplete.** 3 newly recorded entries.

**Searches:** ClinicalTrials.gov interventional discovery, LastUpdatePostDate September 5–October 9; updated named records from current topic pages.; Dated official sponsor, regulator, trial/publication, conference and original informal-source searches, with October 7–9 prioritized after the October 6 review.

**Remaining gaps:** New condition baseline remains incomplete. Reviewed inherited hub, preceding 90-day development leads and selected older pivotal/contextual sources; October 6 findings deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; All seven matches in bounded RLS discovery downloaded; selected relevant records screened. Selected older trial/guideline anchors added; full drug/iron labeling, safety, pediatric/pregnancy and older trial corpus remain incomplete. Venous-ablation full methods/harms gap persists; no cure conclusion.

**Informal sources and unresolved claims:** Original October 7 RLS algorithm thread led to a verified May 26 original publication. Individual October device/medication experiences are not trial efficacy. Full SLEEP/SOS recordings and podcast interviews remain incomplete.

**Sources checked:**

- [Source 1](https://clinicaltrials.gov/api/v2/studies/NCT04874155)
- [Source 2](https://clinicaltrials.gov/api/v2/studies/NCT05196828)
- [Source 3](https://clinicaltrials.gov/api/v2/studies/NCT07675109)
- [Source 4](https://clinicaltrials.gov/api/v2/studies/NCT07822607)
- [Source 5](https://clinicaltrials.gov/api/v2/studies?query.term=%28restless+legs+syndrome%29+AND+AREA%5BStudyType%5DINTERVENTIONAL+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-09%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true)
- [Source 6](https://pubmed.ncbi.nlm.nih.gov/42203073/)
- [Source 7](https://doi.org/10.1016/j.mayocp.2026.05.010)
- [Source 8](https://www.reddit.com/r/RestlessLegs/comments/1x0bai6/an_updated_algorithm_for_the_management_of/)
- [Source 9](https://clinicaltrials.gov/study/NCT07224932)
- [Source 10](https://clinicaltrials.gov/study/NCT07780032)

## Homepage review and public edition

The October 3 EloraTZP feature is retained after six days: it presents a recent active-comparator trial with matching-arm tolerability. New result ranges without dose mapping or analysis details are not converted into invented plotted points. Historical curves, intervals, trial populations and source dates remain unchanged. A background run skips user-facing browser handoff; release checks and native publication status are separate from browser QA. The publication receipt is recorded in state.json only after success.